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Objective: To respond to a pre-speciﬁed set of questions posed by the United States Food and Drug
Administration (FDA) on deﬁning the disease state to inform the clinical development of drugs, biological
products, and medical devices for the prevention and treatment of osteoarthritis (OA).
Methods: An Osteoarthritis Research Society International (OARSI) Disease State working group was
established, comprised of representatives from academia and industry. The Working Group met in
person and by teleconference on several occasions from the Spring of 2008 through the Autumn of 2009
to develop consensus-based, evidence-informed responses to these questions. A report was presented at
a public forum in December 2009 and accepted by the OARSI Board of Directors in the Summer of 2010.
Results: An operational deﬁnition of OA was developed incorporating current understanding of the
condition. The structural changes that characterize OA at the joint level were distinguished from the
patients’ experience of OA as the ‘disease’ and ‘illness’, respectively. Recommendations were made
regarding the evaluation of both in future OA clinical trials. The current poor understanding of the
phenotypes that characterize OA was identiﬁed as an important area for future research.
Conclusions: The design and conduct of clinical trials for new OA treatments should address the
heterogeneity of the disease, treatment-associated structural changes in target joints and patient-
reported outcomes.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In 2007, the United States Food and Drug Administration (FDA)
published a request for proposals to conduct a critical appraisal
providing information on various issues related to clinical devel-
opment programs for drugs, biological products, and medical
devices for the prevention and treatment of osteoarthritis (OA). The
Osteoarthritis Research Society International (OARSI) was selected
to prepare the response to these issues and, in 2008, constituted an
Executive Committee, Steering Committee and eight Working
Groups to address questions posed by the FDA1. One of these
Working Groups, “Deﬁning Disease State” was asked to provideN.E. Lane, Endowed Professor
ine, University of California at
A. Tel: 1-916-734-0758; Fax:
s Research Society International. Precommendations based on current evidence on a pre-speciﬁed set
of issues:
 What is OA?
 How do we deﬁne OA for the purposes of treatment or
prevention?
 Are oligoarticular, monoarticular and polyarticular OA the
same disease?
 Is hand OA different than hip OA and knee OA?
 Where does degenerative disc disease (DDD) ﬁt in?
 How many sites need to be studied for approval of: a systemic
(oral) therapy? How many for a local therapy?
 Should there be uniform inclusion and exclusion criteria for OA
clinical trials?
 What is the research agenda required to inform each of the
above questions?
This document summarizes the group’s recommendations to
the FDA.ublished by Elsevier Ltd. All rights reserved.
N.E. Lane et al. / Osteoarthritis and Cartilage 19 (2011) 478e482 479Methods
The Disease State Working Group was assembled by the project
Steering and Executive Committees to ensure adequate represen-
tations from academia and industry. The Working Group met in
person and by teleconference on several occasions from the Spring
of 2008 through the Autumn of 2009 to develop consensus-based,
evidence-informed responses to these questions. A report was
presented at a public forum in December 2009 and accepted by the
OARSI Board of Directors in the Summer of 2010.Results
What is OA?
Deﬁning OA has important implications for prevention, diag-
nosis, and treatment of this condition. Based on evidence to date,
there was consensus that OA is usually a progressive disease of
synovial joints that represents failed repair of joint damage that
results from stresses that may be initiated by an abnormality in any
of the synovial joint tissues, including articular cartilage, sub-
chondral bone2e4, ligaments, menisci (when present)5,6, peri-
articular muscles7, peripheral nerves, or synovium8,9. This
ultimately results in the breakdown of cartilage and bone10, leading
to symptoms of pain, stiffness and functional disability11. Abnormal
intra-articular stress and failure of repair may arise as a result of
biomechanical12, biochemical13 and/or genetic factors14. This
process may be localized to a single joint, a few joints, or general-
ized, and the factors that initiate OA likely vary depending on the
joint site. The complexity and variability of OA etiology suggests the
need for patient-speciﬁc, etiology-based treatment.How do we deﬁne OA for the purposes of treatment or prevention?
While late-stage OA is often characterized by both demonstrable
structural damage and patient reports of joint pain, stiffness and
disability17. There is only a weak correlation between symptoms
and pathology, particularly in early stages of the disease18. Further,
FDA-approved treatments directed at reducing the symptoms of OA
have not been shown, to date, to prevent ongoing joint structural
damage. For this reason, the Working Group felt that future
development of treatments for OA should consider the effects of
the treatment on the structural changes at the joint level (the
disease OA) separately from the effects on patient-reported symp-
toms (the illness OA). Future pharmacotherapy for OA may there-
fore be considered to be ‘structure modifying’ (i.e., designed to
prevent the development of joint failure), symptom modifying, or
both.
Classiﬁcation of patients based on the presence/absence of the
disease (structural changes demonstrated on imaging studies) and
the illness (patient-reported symptoms of OA) may be useful in trial
design and recruitment. For example, in the absence of longitudinal
observations of asymptomatic non-arthritic individuals who have
recognized risk factors for OA, it may be difﬁcult to differentiate
pathology that increases intra-articular stress and thus the risk for
OA (e.g., abnormalities in bone shape, such as subtle acetabular
dysplasia) from pathologic changes of OA that are a consequence of
the damage caused by an increase in intra-articular stress (e.g.,
bony remodeling that may occur in response to abnormal stress or
meniscal degeneration)19. Studying subjects with neither structural
changes nor symptoms would be most appropriate for primary
prevention studies, those with only the ‘disease’ for interventions
designed to prevent symptomatic OA, and studies of those with
both the illness and disease for treatments designed to preventjoint failure, deﬁned, for example, as the need for total joint
replacement.
Considerations regarding the disease
The proposed deﬁnition of OA, above, incorporates the current
understanding of the role of intra-articular stress, whichmay result
from abnormal biomechanical forces, in the etiology of OA. In knee
OA, biomechanical changes, including varus/valgus angulation20
and rotational abnormalities after acute anterior cruciate liga-
ment injury21, contribute to OA progression andmay serve as useful
biomarkers of structural damage22. Due to the strong inﬂuence of
these biomechanical changes on OA progression, the type and the
degree of abnormality (e.g., varus/valgus deformity) should be
included in the deﬁnition of OA since theymay inﬂuence treatment
outcome.
However, while substantial progress has been made in this area,
knowledge gaps remain regarding the inﬂuence of corrections to
joint loading on structural changes in OA, including whether or not
relief of joint pain and improvement in function are outcomes of
the structural healing process. Promising work evaluating biome-
chanics of the knee and hip via functional gait analysis, stereo
ﬂuoroscopy, and adduction moment analysis may ultimately
permit identiﬁcation of risk factors or markers of joint abnormality
that contribute to the development of OA20,23e25. Adequately pow-
ered, randomized, controlled trials in patients with symptomatic
knee OA may help to determine whether amelioration of impulsive
loads and/or peak dynamic loading reduces joint pain and improves
function, and thus could serve as alternatives to pharmacologic
therapies.
As OA is characterized by synovial joint abnormalities that may
include structural and compositional changes to bone, cartilage,
meniscus, synovium, and other soft tissues of the joint3e5,26,27,
deﬁning joint abnormality in OA by plain X-ray evaluation alone
does not provide a complete description of the disease; changes to
soft tissues in the joint cannot be visualized on plain ﬁlm X-rays.
Indeed, the destruction and loss of cartilage characteristic of knee
OA is often inferred from narrowing of the tibio-femoral joint,
which reﬂects loss of tissue from the joint space28e30. However,
destruction and loss of cartilage and meniscus in the joint space is
characteristic of late-stage disease11. The Working Group agreed
that additional objective criteria, beyond plain radiographs, such as
use of other imaging techniques, including magnetic resonance
imaging (MRI), and molecular biomarkers e the focus of other FDA
OA working groups e are needed to characterize and deﬁne the
onset and early progression of OA19, when intervention may be
more likely to achieve joint preservation. It is hoped that the
deﬁnition of OA will continue to evolve to encompass these new
biomarkers, once identiﬁed and validated, and contribute to our
understanding of the pathobiology of OA in different patients.
Considerations regarding the illness
OA is characterized by joint pain, stiffness and functional limi-
tations resulting in reduced participation in valued activities, and
downstream effects on fatigue, mood, sleep and overall quality of
life31,32. Symptom onset may occur years after that for OA disease,
when structural deterioration is more difﬁcult to treat. The symp-
toms of OA are largely evaluated using patient self-report measures,
scores on which may be inﬂuenced by a number of factors, e.g.,
measures of coping33, and by performance-based measures of
physical functioning. Consideration of the inﬂuence of these other
factors on treatment response is important in the evaluation of OA
treatments.
Traditionally, OA treatment studies have focused on pain
intensity and/or physical functioning as their primary outcomes of
interest. However, this approach fails to consider the full OA illness
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presence and severity of additional common features of OA to
determine which aspect(s) of the illness (e.g., pain, sleep quality,
depressed mood) that a given intervention may improve, and those
for which it is unlikely to provide beneﬁt. This approach may
ultimately permit treatment to be matched to the symptoms that
are most important to the patient.
Among those who seek help from a physician, joint pain is the
most common complaint34. Although OA-related pain has tradi-
tionally been assumed to be nociceptive in origin, resulting from
joint tissue destruction35, there is increasing evidence from both
animal and human studies that neuropathic type pain exists in
some individuals with OA, likely due to peripheral and/or central
pain sensitization35,36. Thus, OA patients may have pain that is
predominantly nociceptive, predominantly neuropathic, or of
mixed nociceptive/neuropathic etiology. Research is under way to
further elucidate pain mechanisms in OA, and to facilitate better
characterization of the nature of the pain in OA patients. Ultimately,
the goal will be to stratify OA patients in intervention trials on the
basis of the type of pain present, with the goal of better targeting
pain therapies to individual patients.
OA most commonly affects older adults, who often have co-
morbid medical conditions. Both age and co-morbidity may inde-
pendently inﬂuence, or be associated with, pain, fatigue, depressed
or anxious mood, muscle strength, ﬁtness, and level of physical
activity. While it is often difﬁcult to distinguish OA-related effects
from those of other conditions, clinical trials evaluating the efﬁcacy
and safety of treatments for OA should consider these issues. The
heterogeneity of the pathophysiology of OA may further impact
variability in response to treatment outcomes in clinical trials of
OA; such heterogeneity may be reduced in the future by improved
phenotyping of OA that enables focused recruitment of subjects
with the same ‘phenotype’.Are oligoarticular/monoarticular and polyarticular OA the same
disease? Is hand OA different from hip OA and from knee OA?
Existing data are insufﬁcient to answer these questions. Which
OA joints and/or patterns of OA joint involvement are associated
with greater illness than others is not well understood. Further-
more, it remains unclear whether erosive hand OA is part of
a spectrum of nodal hand OA or a distinct entity. As noted above, OA
has no common etiology; it is likely that the risk factors for both
structural changes and symptoms of OA differ not only for different
joints, for example, because of differences in the local protective
mechanisms16, but even within a single joint (e.g., varus mala-
lignment leading to medial tibiofemoral changes and lateral
meniscal tear inciting lateral tibiofemoral disease). As a result,
therapeutic responses are likely to vary.
In this respect, there is a growing consensus that OA is not
a single disease of the joints, but rather a collection of diseases with
many causes and potential treatments15,37. The concept of “OA
phenotypes” has been advanced to address the variability of OA
with respect to pattern and site of joint involvement (knee, hand,
hip, spine) and characteristics (inﬂammation, mal-alignment,
cartilage erosion, osteophyte formation)38e41. There is an urgent
need for improved characterization of these OA phenotypes; until
such work is completed, trials in OA should evaluate a primary joint
site, but should ideally also collect data on the presence/absence of
structural changes and symptoms at other typical OA sites, e.g.,
using a joint homunculus. This would enable evaluation of the
effect of new interventions on incident OA as well as the number of
OA joints that undergo signiﬁcant progression over the treatment
period.Where does DDD ﬁt in?
Spinal OA refers to the degeneration of the cartilage and
surrounding tissues in the synovial facet joints of the spine42. DDD
describes the deterioration of the intervertebral disc. While
advanced DDD can contribute to the onset of spinal OA, and while
the two conditions are often seen together43, DDD and spinal OA
are anatomically distinct. DDD treatments currently in develop-
ment are aimed at restoring disc height. However, it is unclear
whether the restoration of disc anatomy will result in signiﬁcant
pain relief44.
Identifying the source of back pain in patients with facet joint
OA and DDD remains a challenge. As for peripheral joint OA, there is
a lack of concordance between symptoms and structural changes
on radiographs in spinal OA; many patients with advanced facet
joint OA and/or DDD have no symptoms, while others with only
mild structural changes present with extreme pain and disability42.
Further complicating matters, many factors other than OA or DDD
can contribute to back pain, including vertebral fracture, congenital
spinal deformity, and muscle strains and imbalances.
Back pain resulting fromDDD, facet joint OA, or other conditions
is often present in patients with OA involving other joints, partic-
ularly the knee43. The relationship between knee pain and back
pain is complex and not well understood. Both back and knee pain
can result in gait changes that can negatively impact each other. OA
is often polyarticular and may be present in facet joints and knees
in the same patient. Due to the complex and inconsistent rela-
tionships among DDD, facet joint OA, back pain, and extremity pain,
DDD should be considered separately. Relief of pain speciﬁcally
from DDD, as well as therapies directed towards disc restoration,
should be addressed in separate clinical trials. However, due to the
high frequency of concomitant back pain in individuals with lower
extremity OA, and the potential for back pain to inﬂuence OA
treatment effects, clinical trials should ascertain the presence of
back pain as a potential confounder, and possibly the effect of OA
therapies on back pain, when present, but only as secondary or
tertiary endpoints.
How many joints need to be studied for regulatory approval of an
oral therapy? For a local therapy?
An advantage of a systemic oral therapy is the potential to treat
multiple arthritic joints in the same patient. A potential disadvan-
tage to this approach is the difﬁculty in achieving sufﬁcient
concentrations for efﬁcacy in the target joints. Local therapies,
including intra-articular and topical therapies, can achieve high
concentrations in speciﬁc joints but may require multiple treat-
ments. In either case, because of the variability in causes and
characteristics of OA between joints, efﬁcacy in one joint does not
assure efﬁcacy in another. Thus, approval of local therapies should
be based on joint-speciﬁc efﬁcacy. With systemic treatment,
however, more than one joint could be evaluated.
Should there be a uniform deﬁnition of inclusion and exclusion
criteria in OA clinical trials?
Inclusion and exclusion criteria should be joint-speciﬁc,
reﬂecting factors that are known to affect the incidence and
progression of OA in that joint. Inclusion and exclusion criteria for
clinical trials may also vary, based on the mechanism of action of
the drug or device being studied. It is recommended that inclusion/
exclusion criteria be similar for therapeutic interventions with the
same mechanism of action. To permit comparison between agents,
assessment for systemic toxicity should be as similar as possible for
all interventions.
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questions?
To standardize the evaluation of OA, research is needed to:
1. Deﬁne the phenotypes of OA. Such phenotypes should ideally
take into consideration the patterns and sites of joint involve-
ment, pathophysiology, clinical presentation (e.g., severity and
quality of pain), the presence of speciﬁc distinguishing
biomarkers, and potentially rate of progression/prognosis.
Information on genotypes linked to differences in OA onset and
progression may help to further reﬁne the OA phenotypes and
improve study subject selection.
2. Gain consensus on a core set of measures to evaluate the
spectrum of the illness OA beyond pain intensity and physical
disability. Speciﬁcally, research is needed to develop and test
measures to evaluate changes in response to treatment in OA-
related fatigue, poor sleep, depressed and anxious mood, and
participation in valued activities.
Conclusions
Over the past decade, the paradigm has shifted away from
a ‘chondrocentric’ view of OA, with recognition that OA is
a complex disease with no common pathological pathway.
However, biomechanical joint stress has a substantial etiologic role.
Because risk factors for OA differ not only for different joints, but
even within a single joint, therapeutic responses may vary. More
recently, the concept of OA as a disease, manifest in the structural
changes occurring at the joint level, and an illness, reﬂecting the
patient’s experience living with OA, has evolved, with the recog-
nition that OA interventions may have discordant effects on OA
illness vs disease.
Therefore, both should be considered in development and
evaluation of new therapeutic interventions. Finally, the hetero-
geneity of OA as an entity, and the resulting inherent difﬁculty in
classifying patients into distinct subgroups or phenotypes, has
prevented the targeting of clinical trials of OA therapies to those OA
phenotypes most likely to beneﬁt and may explain, in part, the
relatively modest effect sizes of most OA therapies to date45.
Improved understanding of the phenotypes of OA has the potential
to enhance the speciﬁcity of treatment selection and is sorely
needed.
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